Zelluna ASA Logo

Zelluna ASA

Develops off-the-shelf, TCR-guided NK cell immunotherapies for solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo

Description

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 17:26
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the U…
English 6.1 KB
2025-12-17 17:26
Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Sto…
Norwegian 6.4 KB
2025-12-16 12:36
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First M…
Norwegian 6.6 KB
2025-12-12 13:02
Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to …
English 4.7 KB
2025-12-09 09:36
Zelluna ASA: Cancellation of subsequent repair offering
English 1.8 KB
2025-12-09 08:22
Financial calendar
English 749 bytes
2025-12-08 18:36
Zelluna ASA - Mandatory notification of trade - Attachment: PDMR attachment.pdf
English 102.0 KB
2025-12-08 18:36
Zelluna ASA - Mandatory notification of trade
English 579 bytes
2025-12-08 13:52
Zelluna ASA: New share capital registered
English 2.4 KB
2025-11-28 07:50
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financia…
English 4.2 KB
2025-11-27 08:35
Zelluna ASA: Disclosure of large shareholding
English 1.8 KB
2025-11-25 16:05
Zelluna ASA: Disclosure of large shareholding
English 1.4 KB
2025-11-25 12:09
ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING
English 1.5 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
English 325.0 KB
2025-11-25 11:32
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
Norwegian 258.2 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zelluna ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.